Wells Fargo & Company Cuts Solventum (NYSE:SOLV) Price Target to $70.00

Solventum (NYSE:SOLV) had its price target lowered by Wells Fargo & Company from $83.00 to $70.00 in a report published on Wednesday,Benzinga reports. The firm currently has an equal weight rating on the stock.

Other research analysts have also recently issued reports about the company. Rothschild & Co Redburn began coverage on Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target for the company. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Piper Sandler lowered their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Finally, Stifel Nicolaus raised their target price on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $85.91.

Solventum Stock Up 2.3%

Shares of SOLV opened at $73.30 on Wednesday. Solventum has a 52 week low of $62.38 and a 52 week high of $88.20. The stock has a market capitalization of $12.69 billion, a price-to-earnings ratio of 8.98, a PEG ratio of 1.10 and a beta of 0.59. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.89 and a current ratio of 1.07. The stock has a fifty day moving average of $67.84 and a 200-day moving average of $74.50.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the prior year, the company earned $1.34 EPS. Solventum’s revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, sell-side analysts anticipate that Solventum will post 6.59 earnings per share for the current fiscal year.

Insider Transactions at Solventum

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the transaction, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.24% of the stock is currently owned by corporate insiders.

Institutional Trading of Solventum

A number of large investors have recently bought and sold shares of SOLV. Independent Franchise Partners LLP grew its holdings in Solventum by 27.2% during the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock worth $941,645,000 after acquiring an additional 2,758,174 shares during the period. Norges Bank acquired a new stake in Solventum during the 4th quarter worth about $147,467,000. Diamond Hill Capital Management Inc. grew its holdings in Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock worth $167,119,000 after acquiring an additional 1,272,921 shares during the period. Boston Partners grew its holdings in Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after acquiring an additional 959,543 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after acquiring an additional 867,837 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.